NVZMY Maintained at Buy by Citigroup, May 2026

Citigroup maintained its Buy rating on Novozymes A/S (NVZMY) on May 8, 2026, signaling confidence in the industrial enzyme maker despite near-term market volatility. The analyst firm raised its price target to DKK 440 from DKK 415, reflecting optimism about the company’s long-term growth prospects. NVZMY trades at $59.69 with a market cap of $27.8 billion. The maintained rating comes as the specialty chemicals company continues to expand its portfolio across food, household care, agriculture, and pharmaceutical solutions globally.

NVZMY Maintained Rating and Price Target Increase

Citigroup’s Confidence in NVZMY

Citigroup’s decision to maintain NVZMY at Buy while raising the price target reflects analyst confidence in Novozymes’ strategic positioning. The DKK 25 increase in the target price suggests the firm sees upside potential despite current market conditions. This maintained rating places NVZMY among four Buy ratings in analyst consensus, with only one Sell rating offsetting bullish sentiment.

Current Trading Dynamics

NVZMY closed at $59.69 on May 9, 2026, up 2.17% from the previous session. The stock trades near its 50-day average of $58.40 but remains below its 52-week high of $75.99. Trading volume sits at 37,691 shares, below the average of 117,424, indicating moderate investor interest in the maintained rating.

Meyka AI Stock Grade and Fundamental Metrics

Meyka Grade Assessment

Meyka AI rates NVZMY with a grade of B, suggesting a Hold recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score of 69.96 out of 100 reflects solid fundamentals with room for improvement. These grades are not guaranteed and we are not financial advisors.

Key Financial Metrics

NVZMY trades at a P/E ratio of 39.27, indicating premium valuation relative to earnings. The company generates $23.75 in revenue per share and maintains a 1.68% dividend yield. Free cash flow per share stands at $6.72, while the debt-to-equity ratio of 0.29 shows conservative leverage. NVZMY demonstrates solid operational efficiency with a gross profit margin of 52.3%.

Growth Prospects and Analyst Consensus

Revenue and Earnings Momentum

Novozymes posted strong recent growth with net income up 90.8% year-over-year and EPS growth of 86.6%. Revenue grew 8.5%, while EBIT surged 64.5%, demonstrating operational leverage. The company’s three-year revenue growth per share reached 17.7%, showing acceleration in recent periods. Citigroup raised the price target to DKK 440, reflecting confidence in this momentum.

Analyst Consensus and Valuation

With four Buy ratings and one Sell, the consensus score of 3.0 leans bullish. The maintained rating from Citigroup aligns with broader market optimism about specialty chemicals demand. Forecasts suggest NVZMY could reach $72.55 within one year and $96.29 within five years, implying significant upside from current levels.

Industry Position and Risk Factors

Specialty Chemicals Leadership

Novozymes operates in the Chemicals – Specialty sector within Basic Materials, serving diverse end markets. The company’s enzyme solutions address food, household care, agriculture, pharmaceuticals, and industrial applications. With 10,582 full-time employees and operations across six continents, NVZMY maintains a strong competitive position. The company’s 1.67x current ratio ensures adequate liquidity for operations and growth investments.

Valuation and Technical Considerations

The P/B ratio of 2.16 suggests the stock trades at a premium to book value, typical for quality specialty chemical companies. Technical indicators show mixed signals: RSI at 47.98 indicates neutral momentum, while MACD shows slight bearish divergence. The stock remains within Bollinger Bands, suggesting consolidation before potential breakout.

Final Thoughts

Citigroup’s maintained Buy rating and raised price target underscore confidence in Novozymes’ long-term value creation despite near-term market headwinds. The DKK 25 price target increase reflects optimism about the company’s growth trajectory across multiple end markets. With strong earnings momentum, solid cash generation, and a B-grade from Meyka AI, NVZMY presents a balanced risk-reward profile for investors. The maintained rating aligns with four Buy recommendations in analyst consensus, though the premium valuation warrants careful consideration. Investors should monitor upcoming earnings announcements and macroeconomic trends affecting specialty chemicals demand.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.